Disease burden among patients with atopic dermatitis treated…
Emerging
5
Citations33
Refs2023
Year
Search Works
Work Details
- DOI 10.1080/09546634.2023.2246601
- PMID https://pubmed.ncbi.nlm.nih.gov/37691405
- OpenAlex ID W4386593115
- Type Article
- Language EN
- Published 10 Sep 2023
- Volume 34 (1)
- Pages 2246601
- Source Journal of Dermatological Treatment
- Publisher Informa
- FWCI 1.39
- Countries 2
- Institutions 5
- Added 12 Sep 2023
- Updated 01 Oct 2026
External Links
MENU
0
Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry
Article 2023 EN Diamond
Background Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited.Methods Adult patients with AD in the CorEvitas AD registry (2020–2021) who received systemic therapies for 4–12 months prior to enrollment were included based on disease severity: body surface area (BSA) 0%–9% and BSA ≥10%. Demographics, clinical characteristics, and outcomes were assessed us…
5
Citations
33
References
8
Authors
1.39
FWCI
Citations by Year
Last 3 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
8 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Jonathan I. Silverberg Corresponding | George Washington University (US) | |
| 2 | Evangeline J. Pierce | Eli Lilly (United States) (US) | |
| 3 | Meghan A. Feely | Mount Sinai Hospital (CA) Mount Sinai Hospital (US) +1 | — |
| 4 | Amber Reck Atwater | Eli Lilly (United States) (US) | |
| 5 | Amy M. Schrader | — | — |
| 6 | Eric A. Jones | — | — |
| 7 | Swapna S. Dave | — | |
| 8 | Eric Lawrence Simpson | Oregon Health & Science Univer… (US) |
Related Works
10Data: OpenAlex